Tocilizumab has been reported to attenuate the “cytokine storm” in COVID-19 patients. We
attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and …

Introduction No therapy has proven to be effective yet to reduce mortality and/or invasive
mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with …

Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …

Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a
common presentation of coronavirus disease 2019 (COVID-19). Objective To determine …

This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …

Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU
admission and mortality rate of critically ill patients with severe COVID-19 pneumonia …

Background High levels of serum interleukin-6 (IL-6) correlate with disease severity in
COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) …

Objectives To describe the clinical characteristics and predictors of major outcomes in
patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. Patients and …

Elevated concentrations of interleukin-6 have been demonstrated to be an important key
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …